New research reveals that inherited genetics can significantly impact the safety and efficacy of CAR-T cell therapy for blood cancers like lymphoma. Conducted by Mass General Brigham Cancer Institute and others, the study highlights the need for personalized approaches in CAR-T cell treatment to mitigate side effects and enhance patient outcomes.
Chimeric antigen receptor (CAR)-T cell therapy, which reprograms an individual's immune cells to seek out and destroy certain cancer cells, has revolutionized treatment for blood cancers such as lymphoma. Chimeric antigen receptor (CAR)-T cell therapy, which reprograms an individual's immune cells to seek out and destroy certain cancer cells, has revolutionized treatment for blood cancers such as lymphoma. But in some patients, the treatment can cause serious side effects. New research led by investigators at the Mass General Brigham Cancer Institute, the Broad Institute of MIT and Harvard, and Dana-Farber Cancer Institute has shown that patients' inherited genetic makeup can influence whether they benefit from CAR-T cell therapy or experience toxicity from the treatment. These findings have important implications for understanding how CAR-T cells behave in patients since each CAR-T cell product is unique to the person from whom it is manufactured, unlike all prior forms of therapy, which are identical across patients." Mark B. Leick, MD, lead author, oncologist, Mass General Brigham Cancer Institute For the study, Leick and his colleagues sequenced the entire genomes of more than 200 patients with aggressive lymphoma from two major clinical trials of CAR-T cell therapy. In one of the trials, patients with T cells with variants that silenced the STXBP2 gene tended to experience toxicity related to CAR-T cell therapy. In both clinical trials, variants in the ADAMTSL3 gene correlated with protection from treatment-related toxicity, and variants in the PTPN22 gene were strongly associated with enhanced CAR T-cell expansion, which correlates with effective therapy.
Original title: “Inherited genetics can influence safety and success of CAR-T cell therapy”